The Barometer Program

Meet our Leadership Coalition

Professor Paul Mitchell

Emeritus Professor of Ophthalmology, University of Sydney, Australia
Consultant Ophthalmologist, Western Sydney Local Health District, Australia
Principal, Sydney West Retina Pty Ltd, Australia

Paul Mitchell is Emeritus Professor of Ophthalmology at the University of Sydney (Westmead Hospital) in Sydney, Australia. He works as a medical retina specialist heading the Sydney West Retina retinal practice, and has been appointed Senior Principal Research Scientist at the Singapore Eye Research Institute. Furthermore, he was previously a long-standing Director of Ophthalmology for the Sydney West Local Health District, where he continues to consult.

Professor Mitchell's clinical focus is the management of age-related macular degeneration (AMD) and diabetic retinopathy (DR), particularly using anti-vascular endothelial growth factor therapy, as well as other vascular retinopathies and systemic disease effects on the eye. He has co-authored 1,145 peer-reviewed papers across all major eye journals, as well as leading medical journals, including *New England Journal of Medicine* and *The Lancet*. Further, he has co-authored over 75 books, chapters, and letters, and currently has 105,000 citations to his work. He has been the recipient of many awards and prizes throughout his career, and is a past Association for Research in Vision & Ophthalmology Trustee and Vice President.

Professor Mitchell has made significant contributions in the fields of public health and ophthalmic epidemiology via the landmark Blue Mountains Eye Study, and has conducted considerable research into childhood eye conditions via the Sydney Childhood Eye Study. He also has a strong interest in the development, evaluation, and application of evidence-based medicine in ophthalmology, particularly in new therapies for AMD, DR, diabetic macular edema, retinal vein occlusion, and other retinal diseases. Recent work has led to a series of papers covering the cost-effectiveness of therapies for retinal disease, and he has a strong interest in health economics as it applies to treatments to prevent blindness and visual impairment.